Related Experiment Video

Updated: Aug 24, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Effects of HMG-CoA reductase inhibitor on hemostasis

K K Koh1

  • 1Division of Cardiology, Heart Center, Gachon Medical School, 1198 Kuwol-dong, Namdong-gu, 405-760, Inchon, South Korea. kwangk@ghil.com

International Journal of Cardiology
|December 21, 2000
PubMed

Insights

Statins, or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, improve cardiovascular health beyond lowering LDL cholesterol. These drugs may also benefit hemostasis, impacting platelet activation and thrombus formation to reduce atherosclerosis progression.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Hemostasis Research

Background:

  • Statins (HMG-CoA reductase inhibitors) reduce cardiovascular events and slow coronary atherosclerosis.
  • Cardiovascular outcome improvements are not fully explained by LDL cholesterol reduction alone.
  • Non-lipid-lowering effects of statins, particularly on hemostasis, are increasingly recognized.

Purpose of the Study:

  • To explore the potential non-lipid-mediated mechanisms of statin therapy.
  • To investigate the role of statins in modifying hemostasis.
  • To understand how statins may influence platelet activation and thrombus formation in atherosclerosis.

Main Methods:

  • Review of clinical trial data on statin therapy.
  • Analysis of studies investigating statin effects on hemostatic pathways.
  • Examination of the pathophysiology of plaque rupture and thrombosis in coronary heart disease.

Main Results:

  • Statin therapy shows benefits in coronary atherosclerosis progression and cardiovascular event reduction.
  • Evidence suggests statins exert favorable effects on hemostasis.
  • These effects may involve modulation of platelet activation and thrombus formation.

Conclusions:

  • Statin-induced improvements in cardiovascular endpoints may be partly attributed to favorable effects on hemostasis.
  • Modulation of hemostasis by statins could be a significant factor in delaying atherosclerosis progression and clinical manifestations.
  • Further research into statins' non-lipid effects is warranted to fully elucidate their cardiovascular benefits.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...